

Francesco Orio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6763229/publications.pdf>

Version: 2024-02-01

31
papers

2,615
citations

201385

27
h-index

395343

33
g-index

33
all docs

33
docs citations

33
times ranked

2861
citing authors

#	ARTICLE	IF	CITATIONS
1	Expertsâ€™ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 255-274.	1.5	45
2	Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition, 2018, 58, 3141-3158.	5.4	74
3	Low vitamin D status and obesity: Role of nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 215-225.	2.6	116
4	Inositols in the Treatment of Insulin-Mediated Diseases. International Journal of Endocrinology, 2016, 2016, 1-6.	0.6	42
5	Endocrine Aspects of Environmental â€œObesogenâ€•Pollutants. International Journal of Environmental Research and Public Health, 2016, 13, 765.	1.2	63
6	Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update. Journal of Ovarian Research, 2016, 9, 72.	1.3	27
7	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L43-L44.	1.8	3
8	Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells. Scientific World Journal, The, 2014, 2014, 1-13.	0.8	54
9	New guidelines for the diagnosis and treatment of PCOS. Nature Reviews Endocrinology, 2014, 10, 130-132.	4.3	48
10	Bisphenol A in polycystic ovary syndrome and its association with liverâ€™spleen axis. Clinical Endocrinology, 2013, 78, 447-453.	1.2	79
11	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. Journal of Translational Medicine, 2011, 9, 136.	1.8	53
12	Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clinical Endocrinology, 2008, 68, 976-981.	1.2	45
13	Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2008, 69, 792-798.	1.2	85
14	Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. European Journal of Endocrinology, 2007, 157, 69-73.	1.9	41
15	Lack of electrocardiographic changes in women with polycystic ovary syndrome. Clinical Endocrinology, 2007, 67, 46-50.	1.2	5
16	Cardiovascular risk in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S20-S21.	0.5	58
17	Cardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2967-2971.	1.8	70
18	Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6072-6076.	1.8	129

#	ARTICLE	IF	CITATIONS
19	The Increase of Leukocytes as a New Putative Marker of Low-Grade Chronic Inflammation and Early Cardiovascular Risk in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2-5.	1.8	212
20	Endocrine disorders during the first year after autologous stem-cell transplant. <i>American Journal of Medicine</i> , 2005, 118, 664-670.	0.6	42
21	Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4588-4593.	1.8	310
22	Lack of an Association between Peroxisome Proliferator-Activated Receptor- γ Gene Pro12Ala Polymorphism and Adiponectin Levels in the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5110-5115.	1.8	54
23	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. <i>Reproductive BioMedicine Online</i> , 2004, 9, 505-510.	1.1	66
24	The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3696-3701.	1.8	250
25	GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 117-122.	1.8	11
26	Exon 6 and 2 Peroxisome Proliferator-Activated Receptor- γ Polymorphisms in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5887-5892.	1.8	106
27	Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. <i>Human Reproduction</i> , 2003, 18, 1410-1416.	0.4	48
28	Circulating Ghrelin Concentrations in the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 942-945.	1.8	76
29	Homocysteine Levels and C677T Polymorphism of Methylenetetrahydrofolate Reductase in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 673-679.	1.8	85
30	Adiponectin Levels in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2619-2623.	1.8	148
31	High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. <i>Cancer</i> , 2002, 95, 1076-1084.	2.0	155